Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
IPO Year:
Exchange: NASDAQ
Website: liminalbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2021 | Buy → Neutral | H.C. Wainwright |
H.C. Wainwright downgraded Liminal BioSciences from Buy to Neutral
Piper Sandler downgraded Liminal Biosciences from Overweight to Neutral and set a new price target of $4.50 from $22.00 previously
HC Wainwright initiated coverage of Liminal BioSciences with a rating of Buy and set a new price target of $11.00
HC Wainwright & Co. initiated coverage of Liminal Biosciences with a rating of Buy and set a new price target of $11.00
Bloom Burton downgraded Liminal BioSciences from Hold to Sell
LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the "Arrangement"). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Min
LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price o
LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement"). Further
LAVAL, QC and CAMBRIDGE, England, Sept. 12, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange Commission ("SEC") in connection with the previously announced plan of arrangement involving the acquisition by Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., of all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, paya
LAVAL, QC and CAMBRIDGE, England, Aug. 16, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued an interim order (the "Interim Order") in connection with the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Plan of Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or
Provided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist programClosed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide cash runway into December 2023Net loss from continuing operations of CAD 9 million during the quarter ended June, 2023 compared to CAD 6.4 million during the second quarter of 2022Entry into Arrangement Agreement with Structured Alpha LP potentially providing minority shareholders US$8.50 in cash per Common Share LAVAL, QC and CAMBRIDGE, England, Aug. 8, 2023 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company focused
Liminal BioSciences minority shareholders to receive US$8.50 in cash per share in "go private" transaction LAVAL, QC, CAMBRIDGE, England, and TORONTO, July 12, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") (NASDAQ:LMNL) and Structured Alpha LP ("SALP"), a fund managed by Thomvest Asset Management Ltd., today announced that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Common Shares") that it does not already own. Under the terms of the Arrangement Agreement, Liminal BioSciences shareholders (other than SAL
LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 5, 2023. A total of 2,235,519 common shares were voted, representing 72.02% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Against Votes % Votes % Si
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA) enabling preclinical studies of LMNL6511 to support CTA filing for Phase 1 clinical trial in H2 2023Insights gained from In Vivo preclinical studies of LMNL6511 to further refine potential indications' spectrum GPR40 agonist development program on trackLAVAL, QC and CAMBRIDGE, England, June 2, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead preclinical candidate, LMNL6326, for the development of it
GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide cash runway into early 2024Net loss from continuing operations of CAD 7.4 million during the quarter ended March 31, 2023 compared to CAD 11.1 million during the first quarter of 2022LAVAL, QC and CAMBRIDGE, England, May 9, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company focused on discovering and developing distinctive novel small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases
SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)
SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)
SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)
SC 13G/A - Liminal BioSciences Inc. (0001351172) (Subject)
SC 13G/A - Liminal BioSciences Inc. (0001351172) (Subject)
15-12G - Liminal BioSciences Inc. (0001351172) (Filer)
EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)
EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)
EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)
POS AM - Liminal BioSciences Inc. (0001351172) (Filer)
POS AM - Liminal BioSciences Inc. (0001351172) (Filer)
POS AM - Liminal BioSciences Inc. (0001351172) (Filer)
S-8 POS - Liminal BioSciences Inc. (0001351172) (Filer)
6-K - Liminal BioSciences Inc. (0001351172) (Filer)
SC 13E3/A - Liminal BioSciences Inc. (0001351172) (Subject)
LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back.
LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and 647-484-0474, using the following passcode: 722285. An audio replay of the call will be available as of Thursday November
$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the second quarter ended June 30, 2022. Liminal BioSciences will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday August 10, 2022. The telephone numbers to access the conference call are 888-390-0620 and 416-764-8651. An a
LAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10, 2021. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday May 11, 2022. The telephone numbers to access the conference call are 888-394-8218 and 647-484-0475. An audio replay of the call will be available as of Wednesday May 11, 2022 at 11:30 am (ET). The numbers to access the audio replay are 647-436-0148 and 1-888-203-1112 using the following password (9322170 #). A live audio webcast of
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured loan and release of security on the Company's assets Completion of the Phase 1 Multi-Ascending Dose ("MAD") clinical trial of fezagepras Closing of the sale of the plasma-derived therapeutics business and sale of a Rare Pediatric Disease Priority Review Voucher LAVAL, QC, and CAMBRIDGE, England, March 17, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter and year ended December 31, 2021.
Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedrion Closing of the Sale of Plasma Collection Centers to Kedrion Closing of the Sale of Plasma-Derived Therapeutics Manufacturing Facility to Kedrion Signature of Agreement to Sell Rare Pediatric Disease Priority Review Voucher for US$105M LAVAL, QC and CAMBRIDGE, England, Aug. 16, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today reported its financial results for the second quarter ended June
LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 5, 2023. A total of 2,235,519 common shares were voted, representing 72.02% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Against Votes % Votes % Si
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40 agonist for the treatment of type 2 diabetes Closed December 31, 2022 with just over CAD 37 million cash on hand, expecting to provide cash runway into early 2024Net loss from continuing operations of CAD 6.6 million during the quarter ended December 31, 2022 compared to CAD 8.8 million during the fourth quarter of 2021Regained compliance with minimum bid price requirement for continued listing on the Nasdaq Capital MarketCompleted the sale of a non-core real estate asset at
$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023Possibilities to sell non-core assets to further extend runway into 2024Changes to strengthen executive leadership teamLAVAL, QC and CAMBRIDGE, England, Nov. 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today
$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023Possibilities to sell non-core assets to further extend runway into 2024Changes to strengthen executive leadership teamLAVAL, QC and CAMBRIDGE, England, Nov. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"),
LAVAL, QC and CAMBRIDGE, England, June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6, 2022. A total of 20,209,035 common shares were voted, representing 65.10% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Withheld / Abstain Votes %
LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually on June 4, 2021. A total of 22,136,650 common shares were voted, representing 73.93% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Wit
Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement").
Second Quarter Ended June 30th 2023 Financial Results All figures presented in this section are in Canadian dollars. Cash and cash equivalents were $19.3 million at June 30, 2023 while our working capital, i.e., the current assets net of current liabilities, was $16.4 million. Research and development expenses were $4.3 million during the second quarter of 2023 compared to $3.9 million for the second quarter of 2022. The increase of $0.4 million in R&D expenses during the quarter ended June 30, 2023 compared to the corresponding period in 2022 was mainly attributable to an increase of $0.7 million in preclinical studies expense associated with the advancement of our GPR84 and OXER1 anta
Gainers Healthcare Triangle, Inc. (NASDAQ:HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. Ault Alliance, Inc. (NYSE:AULT) gained 73.3% to $5.72 after the company said it anticipates $200 million in annual revenue for 2023. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares climbed 67.3% to $11.34 after the company announced collaboration and a $50 million investment from NVIDIA. Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares surged 45.1% to $2.5239 after gaining 15% on Tuesday. Liminal BioSciences Inc. (NASDAQ:LMNL) rose 39.6% to $8.31 after the company announced it entered into an ar
Liminal BioSciences Inc (NASDAQ:LMNL) shares are trading higher after Structured Alpha, a fund managed by Thomvest Asset Management, agreed to acquire the company. Under the terms of the Arrangement Agreement, Liminal BioSciences shareholders will receive $8.50 in cash per common share, which represents a premium of approximately 135% over Liminal BioSciences' closing share price on April 4, which was the last full trading day before the public announcement of Structured Alpha's initial non-binding proposal. The agreement is $1.00 per share, more than Structured Alpha's initial non-binding proposal. The Special Committee engaged BMO Capital Markets to provide an opinion and an independent
SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Common Shares") that it does not already own.
Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board of directors of the Company has already established a special committee of the independent members of the Company's board of directors (the "Special Committee") in respect to the previously announced unsolicited non-binding proposal from Structured Alpha LP ("SALP") to acquire all of the issued and outstanding common shares of the Company that SALP does not currently own for US$7.50 in cash per common share (the "Proposal"). The Special Committee has retained BMO Capital Markets as its independent financial advisor and to provide a formal valuation of the common shares of the Company
Potential shorts squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze candidates and several stocks to watch this week based on the Fintel short squeeze leaderboard. 1. Getty Images Holdings (NYSE:GETY) tops the short squeeze leaderboard for a fourth straight week. Data shows 100.2% of the float short, up from last week’s 87.7% reported. The cost to borrow on shares is 222.4%, up significantly from last week’s 107.2% reported. Getty Images is no stranger to the list,